FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Naratriptan Hydrochloride Tablets
Status: Discontinuation
»Therapeutic Categories: Neurology

Mylan Pharmaceuticals Inc. (New 12/20/2016)

Company Contact Information:

Presentation Posting Date Related Information
Naratriptan Tablets USP, 2.5 mg, 9s (NDC 0378-4451-59) 12/20/2016 A business decision was made to discontinue manufacture of the drug product. The product discontinuation is not related to product quality, safety or efficacy.

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English